pbs_code
stringlengths 5
6
| drug
stringclasses 17
values | brand
stringclasses 30
values | formulation
stringclasses 37
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 3.47k
3.47k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
12810F | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
10901R | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | psoriatic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12348X | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
12348X | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
12348X | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
12348X | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | First continuing treatment | 14683 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13208E | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | ankylosing spondylitis | Subsequent continuing treatment | 14701 | true | STREAMLINED | Any | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13724H | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12335F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Hadlima | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
12396K | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 3,471 | 2,024 | NOVEMBER |
13350P | upadacitinib | Rinvoq | Tablet 15 mg | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13350P | upadacitinib | Rinvoq | Tablet 15 mg | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13350P | upadacitinib | Rinvoq | Tablet 15 mg | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13350P | upadacitinib | Rinvoq | Tablet 15 mg | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
13692P | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 1 (New patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
11560K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
9662M | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
10890E | secukinumab | Cosentyx | Injection 150 mg in 1 mL pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
9089J | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 3,471 | 2,024 | NOVEMBER |
12406Y | adalimumab | Humira | Injection 20 mg in 0.2 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 3,471 | 2,024 | NOVEMBER |